Huma Therapeutics Limited, a global digital health company, announced on January 9 its acquisition of Alcedis GmbH for an undisclosed price. Through the acquisition, Huma will form an advanced clinical trials division offering digital solutions across the entire development pipeline, from early stage through to Phase IV hybrid and fully decentralized trials.
Alcedis GmbH is a contract research organization (CRO) for data driven clinical research and technology utilization. Headquartered in Hessen, Germany, Alcedis has more than 25 years of clinical trial experience.
Huma Therapeutics produces applications that integrate health data from hospital databases as well as patient wearables and other mobile devices and securely transmits it for use by doctors.
Huma’s modular platforms are used by more than 3,000 hospitals and clinics, with more than 1.8 million active users in health care and more than 650,000 participants across research.
According to data captured from the LevinPro HC database, this marks the third CRO transaction of 2023. There were 39 CRO transactions announced during 2022. In January 2022, Huma purchased iPLATO Healthcare, a patient engagement firm based in London.
